The prostate-specific membrane antigen (PSMA), has emerged as a key target in modern diagnostics and therapy of prostate cancer (PC) [1–5], which is one of the most prevalent malignancies in men worldwide [6]. Here, FOLH1 is linked to pachyonychia congenita.